APA 6th Edition Pavičić Baldani, D., Škrgatić, L., Šimunić, V., Elveđi Gašparović, V. & Geršak, B. (2015). HORMONSKO NADOMJESNO LIJEČENJE I VENSKE TROMBOEMBOLIJE. Liječnički vjesnik, 137 (1-2), 0-0. Retrieved from https://hrcak.srce.hr/172679
MLA 8th Edition Pavičić Baldani, Dinka, et al. "HORMONSKO NADOMJESNO LIJEČENJE I VENSKE TROMBOEMBOLIJE." Liječnički vjesnik, vol. 137, no. 1-2, 2015, pp. 0-0. https://hrcak.srce.hr/172679. Accessed 27 Feb. 2020.
Chicago 17th Edition Pavičić Baldani, Dinka, Lana Škrgatić, Velimir Šimunić, Vesna Elveđi Gašparović and Blaž Geršak. "HORMONSKO NADOMJESNO LIJEČENJE I VENSKE TROMBOEMBOLIJE." Liječnički vjesnik 137, no. 1-2 (2015): 0-0. https://hrcak.srce.hr/172679
Harvard Pavičić Baldani, D., et al. (2015). 'HORMONSKO NADOMJESNO LIJEČENJE I VENSKE TROMBOEMBOLIJE', Liječnički vjesnik, 137(1-2), pp. 0-0. Available at: https://hrcak.srce.hr/172679 (Accessed 27 February 2020)
Vancouver Pavičić Baldani D, Škrgatić L, Šimunić V, Elveđi Gašparović V, Geršak B. HORMONSKO NADOMJESNO LIJEČENJE I VENSKE TROMBOEMBOLIJE. Liječnički vjesnik [Internet]. 2015 [cited 2020 February 27];137(1-2):0-0. Available from: https://hrcak.srce.hr/172679
IEEE D. Pavičić Baldani, L. Škrgatić, V. Šimunić, V. Elveđi Gašparović and B. Geršak, "HORMONSKO NADOMJESNO LIJEČENJE I VENSKE TROMBOEMBOLIJE", Liječnički vjesnik, vol.137, no. 1-2, pp. 0-0, 2015. [Online]. Available: https://hrcak.srce.hr/172679. [Accessed: 27 February 2020]
Abstracts Venous thromboembolism (VTE) is the most important side effect of using hormone replacement therapy (HRT). Biological and epidemiological studies have shown that oral administration of estrogen is associated with an increased risk of VTE compared to transdermal route of administration. Addition of progestogen to estrogen further increases the risk of VTE. Different pharmacological classes of progestogens differently contribute to the risk of VTE. Observational studies observed that the application of micronized progesterone and didrogesteron are safer regarding the risk of VTE compared to other progestins. These results should be further confirmed in the randomized studies. A personal or family history of VTE, existence of hereditary thrombophilia or/and multiple risk factors for VTE represent a strong contraindication to oral HRT use. In such persons the application of transdermal estrogen can be considered after careful individual evaluation of the benefits and risks. Transdermal estrogen should be also the first choice in overweight/obese women requiring HRT.